NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Enochian Biosciences Inc. (“Enochian” or the “Company”). NOV and certain of its officers and directors. The class action, filed in the United States District Court for the Central District of California and filed at 22-cv-01374, is brought on behalf of a class consisting of all persons and entities other than the defendants who purchased or otherwise acquired Enochian securities September 24, 2020 and May 31, 2022, both dates inclusive (the “Collection Period”), in an attempt to recover damages caused by Defendants’ violations of the federal securities laws and remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and certain of its senior officials.

If you are a shareholder who purchased or otherwise acquired Enochian securities during the class action period, you have until September 26, 2022 to ask the court to appoint you as lead plaintiff in the class action. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Persons inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Enochian is a preclinical-stage biotechnology company purportedly discovering and developing pharmaceutical and biological products for the treatment of human immunodeficiency virus, hepatitis B virus, influenza and coronavirus infections, and cancer.

Enochian and its top management have recognized Serhat Gumrukcu (“Gumrukcu”), Enochian’s co-founder and largest shareholder, as the “genius” and “inventor” of the technology and science behind the Company’s product pipeline.

Enochian has several…